Notification of Investor Briefing: ASCO-GU ZIRCON Phase III Results Presentation

Melbourne (Australia) | 10 February 2023

Telix advises that Associate Professor Brian Shuch, MD, Director, Kidney Cancer Program, UCLA Institute of Urologic Oncology (Los Angeles, California) and a Principal Investigator in the Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) will be delivering an oral presentation to the 2023 ASCO GU Symposium being held in San Francisco, CA, on Saturday 18 February at 2.00pm – 2.10pm PDT (Sunday 19 February 9.00am AEDT) as the first presentation in the Renal and Rare Tumors session.

It marks the first time analyses of the primary endpoints and key secondary endpoints of the ZIRCON study ( Identifier: NCT03849118) will be presented to the medical community.

The Company will host an investor briefing with A/Prof Brian Shuch and Dr Colin Hayward, Telix Group Chief Medical Officer on Tuesday 21 February at 8.30am AEDT (Monday 20 February at 4.30pm EST).

The briefing provides an opportunity for investors to hear Dr Shuch’s ASCO-GU presentation and a clinician’s perspective on the clinical utility of this investigational imaging agent. This will be followed by a Q&A session.

Please register at the following link to access the investor briefing:

To read the full ASX release click here